J&J MedTech Hits $34B Sales with 15.8% Cardiovascular Growth
J&J MedTech grew 5.4% to $34B in 2025, with cardiovascular sales up 15.8% to $8.9B after Abiomed and Shockwave deals, but expects $500M in tariffs and China VBP pressures in 2026. Hologic’s $18.3B Blackstone/TPG takeover at $76 per share signals sector consolidation that could intensify competition for Medtronic.
1. J&J MedTech 2025 Performance
The MedTech segment generated $34 billion in 2025 revenues, marking a 5.4% operational increase driven by 15 major product launches and a 15.8% surge to $8.9 billion in cardiovascular sales following the 2022 and 2024 acquisitions of Abiomed and Shockwave.
2. 2026 Outlook and Challenges
J&J projects stronger MedTech growth in 2026 led by new offerings such as VARIPULSE, ETHICON4000 and OASYS MAX, while anticipating about $500 million in tariff costs and ongoing volume-based procurement impacts in China to pressure margins.
3. Hologic Acquisition Deal
Blackstone and TPG agreed to acquire Hologic for $18.3 billion at $76 per share plus up to a $3 contingent value right tied to Breast Health revenue milestones, reflecting the largest medtech takeover in two decades and limited near-term stock upside.
4. Competitive Implications for Medtronic
The scaling of J&J’s cardiovascular leadership and Hologic consolidation may intensify competition in advanced device markets, potentially prompting Medtronic to accelerate innovation or pursue strategic moves to maintain market share.